$PCVX

Wassil Jim sold $111K of PCVX

Wassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares of Vaxcyte, Inc. (PCVX) at an average of $49.52 ($49.40–$50.26, $0.11M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Jun 3, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PCVX
Bearish
medium confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXBearishLow
01

Why it matters

A modest insider sell by a senior officer may prompt short‑term caution among traders, but the overall effect is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance but provides fresh data for monitoring insider activity.

03

What to watch

The COO retains a large stake (158,494 shares) indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: after-market filing on June 3

Background

Form 4 filings provide the first public record of insider transactions, offering transparency into insider sentiment.

Company-level read

Ticker impact

$PCVXBearishMedium confidence
Context

SEC Form 4 disclosed COO Wassil Jim sold 2,250 shares for $111,416, a routine insider sale under $1M.

Expected impact

potential slight downward pressure as the market prices in the insider sell.

Evidence & confidence

Insider sales, especially by a senior officer, are often interpreted as a weak signal, but the amount is small relative to holdings.

Market effects

Minimal impact on the biotech sector; the sale is company‑specific.

No broader regional effect.

Not globally relevant.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, so price impact may be negligible.

Key entities

  • Vaxcyte, Inc.

    Biotech firm developing vaccine technologies, ticker PCVX.

  • Wassil Jim

    Chief Operating Officer of Vaxcyte, reported the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.